TY - JOUR
AU1 - Khademi, Mahsa
AU2 - Babaei, Zeinab
AU3 - Ghorbanhosseini, Seyedeh Sara
AU4 - Emami Razavi, Amirnader
AU5 - Aghaei, Mahmoud
AB - AbbreviationsAUCarea under the ROC curveLECslymphatic endothelial cellsLNlymph nodeLVDlymphatic vessel densityLYVE‐1lymphatic vessel endothelial receptor 1miRsmicroRNAsOCovarian cancerOSoverall survivalPROX1prospero homeobox 1ROCreceiver‐operating characteristic curveVEGF‐Cvascular endothelial growth factor‐CVEGF‐Dvascular endothelial growth factor‐DVEGFR3vascular endothelial growth factor receptor 3INTRODUCTIONOvarian cancer (OC) remains one of the most common and lethal gynecologic malignancies with an estimated 313,959 new cases and 207,252 deaths in 2020.1 Owing to the lack of symptoms and its insidious onset, patients are often diagnosed at advanced clinical stages, which is accompanied by poor outcomes with 5 year survival rates of less than 25%.2 The extent of lymph node (LN) metastasis is an important indicator of OC aggressiveness and is commonly detected in advanced stages of the disease.3,4 However, the molecular pathways that drive LN metastasis in OC are not well defined.5Recent studies have indicated that cancer cells spreading from the primary site to LNs require lymphangiogenesis.6,7 Lymphangiogenesis is the process of new lymphatic vessel formation, which progresses through the growth, migration and sprouting of lymphatic endothelial cells (LECs).7 This process is very active during early development but uncommon in adulthood and is considered a major hallmark of cancer.6,7 A variety of factors, including vascular endothelial growth factor receptor 3 (VEGFR3), Neuropilin 2, prospero homeobox 1 
TI - Molecular mechanisms of miR‐1236 in the assessment of tumor lymphangiogenesis in human ovarian cancer patients
JF - Journal of Gene Medicine
DO - 10.1002/jgm.3480
DA - 2023-05-01
UR - https://www.deepdyve.com/lp/wiley/molecular-mechanisms-of-mir-1236-in-the-assessment-of-tumor-70HK6uVoZX
VL - 25
IS - 5
DP - DeepDyve
ER -